Today, Nutra Pharma Corp., a biotechnology company that develops treatments for AMN, HIV and Multiple Sclerosis, announced the launch of an over-the-counter pain reliever, Cobroxin, for the treatment of Stage 2 chronic pain. Cobroxin is the first clinically approved OTC pain reliever for Stage 2 pain.
The drug, developed by Nutra Pharma’s subsidiary, ReceptoPharm, will be available as an oral spray. It is designed to treat lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia. It will also be available as a topical gel for treating repetitive stress, arthritis, and joint pain.
Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation, commented, “Cobroxin is a next generation pain reliever that addresses physician and consumer demand for a safer and less costly treatment for chronic pain. Cobroxin provides affordable and accessible pain relief for those without healthcare coverage, for those looking for a safer and effective treatment for pain, and for those not receiving effective or lasting relief from OTC NSAIDs.”
Pain, the most common reason patients seek medical care, accounts for half of all physician office visits in the United States. According to the American Pain Foundation, more than 25 million people in the United States experience acute pain as a result of injury or surgery annually. Additionally, more than 50 million people in the United States are affected by ongoing chronic pain.
Current treatments for chronic pain include opiate-based analgesics such as Vicodin, Percocet, and Morphine. Debate surrounding the use of opiates primarily focuses on the negative side effects observed, including nausea, addiction, severe withdrawal symptoms and the buildup of tolerance. By contrast, Cobroxin is an all natural, non-narcotic pain reliever that is long lasting and more potent than Morphine.
CEO of ReceptoPharm, Dr. Paul Reid, stated, “What differentiates Cobroxin from other current analgesics is that it uses a novel mechanism of action discovered from cobra venom peptides for treating pain without the negative side effects observed in current opiate-based analgesics and those containing acetaminophen. With extensive supporting evidence from 46 human clinical studies and a well-defined safety profile, we believe that Cobroxin will soon become the preferred method for treating chronic pain.”
The company plans to begin marketing and selling Cobroxin upon successful submission of final packaging and labeling to the FDA.
Let us hear your thoughts below:
